

Curriculum vitae

Mag. Dr. Marwa Mostageer

Personal Data

Contact University for Continuing Education Krems
Dr. Karl-Dorrek-Strasse 30
3500 Krems
Phone: +43 (0)2732 893-5391
E-Mail: marwa.mostageer@donau-uni.ac.at

Current Positions

2022 Research Scientist

University for Continuing Education, Department for Biomedical Research
Krems, Austria

Education

1999 – 2002 Ph.D. Student at the Centre for Molecular Biology

(Department of Microbiology, Immunobiology and Genetics / University of Vienna) in collaboration with Boehringer Ingelheim Austria
Research field: Downstream analysis of genes overexpressed in cancer

2002 Graduation (Dr.rer.nat.)

1997 – 1998 Diploma student at the Institute of Molecular Biology

(Department for Biochemistry and Cell Biology / University of Vienna)

1998 Graduation (Mag.rer.nat.)

Research field: Selection of cell cycle mutants with the help of 2'-Deoxyadenosine

1993-1998 Studying Genetics at the University of Vienna

1979-1993 German School in Cairo/Egypt (Deutsche Evangelische Oberschule)

1993 German Abitur

Academic and Professional Career

Since 2022 Research Scientist at UWK

University for Continuing Education, Department for Biomedical Research
Research field: Monocyte subset characterization
Krems, Austria

2019-2021 Scientist/Lecturer at FH-Tulln

University of Applied Sciences, Biotech Campus Tulln
Biotechnische Verfahren/ Bio Data Science- Department
Tulln, Austria

2010-2019 Scientist at AFFiRiS

Research fields: Fc ϵ RI α -Adsorber for Apheresis in Allergy
Alternative Carriers for Vaccination

AFFiRiS GmbH

Vienna, Austria

2007-2010 Scientist at f-Star

Research field: Yeast display for the selection of highly affine Fcabs

f-Star Biotechnologische Forschungs-und Entwicklungsges.m.b.H

Vienna, Austria

2004-2007 Lecturer/Scientist at the GUC

Research field: Shistosoma induced bladder cancer

German University Cairo, Faculty of Pharmacy and Biotechnology

Cairo, Egypt

2002-2004 Scientist at Axon Neuroscience GmbH

Research field: molecular biology of Alzheimer`s Disease

Axon Neuroscience GmbH

Vienna, Austria

Peer-Reviewed Articles

Rady M, Mostageer M, Rohde J, Zaghoul A, Knüchel-Clarke R, Saad S, Attia D, Mahran L, Spahn-Langguth H. (2017) Therapy-relevant aberrant expression of MRP3 and BCRP mRNA in TCC-/SCC-bladder cancer tissue of untreated patients. *Oncology reports*, 38: 551-560

Abdel-Haleem A, El-Zeiry M, Mahran L, Abou Aisha K, Rady M, Rohde J, Mostageer M, Spahn-Langguth H. (2011) Expression of RFC/SLC19A1 is associated with Tumor Type in Bladder Cancer Patients. *PLoS one* 6 (7): e21820:1-7.

Wozniak-Knopp G, Bartl S, Bauer A, Mostageer M, Woisetschläger M, Antes B, Ettl K, Kainer M, Weberhofer G, Wiederkum S, Himmler G, Mudde G, Rüker F. (2010) Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu binding sites and antibody properties. *PEDS* 23 (4): 289-97.

Mostageer M, Spahn-Langguth H. (2010) Gentransfer-Arzneimittel zur Anwendung am Menschen // Gene transfer biopharmaceuticals for use in humans. *European Pharmacopoeia*, pp. 6.8/5.14.00.00.

Buhring HJ, Kuci S, Conze T, Rathke G, Bartolovic K, Grunebach F, Scherl-Mostageer M, Brummendorf TH, Schweifer N, Lammers R.(2004) CDCP1 identifies a broad spectrum of normal and malignant stem/progenitor cell subsets of hematopoietic and nonhematopoietic origin. *Stem Cells* 22(3):334-43.

Conze T, Lammers R, Kuci S, Scherl-Mostageer M, Schweifer N, Kanz L, Buhring HJ.(2003) CDCP1 is a novel marker for hematopoietic stem cells. *Ann. N. Y. Acad. Sci.* 996:222-6.

Scherl-Mostageer M, Sommergruber W, Abseher R, Hauptmann R, Ambros P, Schweifer N. (2001) Identification of a novel gene, CDCP1, overexpressed in human colorectal cancer. *Oncogene* 20(32):4402-8.

Patents

Smrzka O, Mostageer M. Alpha chain of the high-affinity IgE receptor (FcεRIα). Priority patent application international code WO/2017/121842, 2017

Schweifer N, Scherl-Mostageer M, Sommergruber W, Abseher R. Tumour-associated antigen (B345), characterised by an amino acid sequence as in seq. id. no. 4. Priority patent application international code WO 02/04508 A1, 2002.